<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of microsporidiosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of microsporidiosis</h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment of microsporidiosis</div><div class="cntnt"><table cellspacing="0"><colgroup width="16%"></colgroup><colgroup span="3" width="28%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Drug</td> <td class="subtitle1">Adult dose</td> <td class="subtitle1">Pediatric dose</td> </tr> <tr> <td class="sublist_other_start" colspan="4"><strong>Ocular</strong> (<em>Encephalitozoon hellem</em>, <em>Encephalitozoon cuniculi</em>, <em>Vittaforma [Nosema] corneae</em>)</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="3">Drug of choice:</td> <td>Fumagillin (Fumidil B) in saline equivalent to fumagillin 70 mcg/mL eye drops*</td> <td>2 drops every 2 hours for 4 days, then 2 drops 4 times per day</td> <td> </td> </tr> <tr> <td colspan="3"><strong>PLUS for management of systemic infection</strong></td> </tr> <tr class="divider_bottom"> <td>Albendazole<sup>¶</sup><sup>Δ</sup></td> <td>400 mg orally with fatty meal twice per day</td> <td>15 mg/kg per day in 2 divided doses (maximum 400 mg/dose)</td> </tr> <tr> <td class="sublist_other_start" colspan="4"><strong>Intestinal</strong> (<em>Enterocytozoon bieneusi</em>,<em> Encephalitozoon [Septata] intestinalis</em>)</td> </tr> <tr> <td class="subtitle3_left" colspan="4"><em>E. bieneusi</em></td> </tr> <tr> <td class="indent2">Drug of choice:</td> <td>Fumagillin<sup>◊</sup></td> <td>20 mg orally three times per day for 14 days</td> <td> </td> </tr> <tr> <td class="subtitle3_left" colspan="4"><em>E. intestinalis</em></td> </tr> <tr class="divider_bottom"> <td class="indent2">Drug of choice:</td> <td>Albendazole<sup>¶</sup><sup>Δ</sup></td> <td>400 mg orally on empty stomach twice per day for 21 days</td> <td>15 mg/kg per day in 2 divided doses (maximum 400 mg/dose)</td> </tr> <tr> <td class="sublist_other_start" colspan="4"><strong>Disseminated</strong> (<em>E. hellem</em>, <em>E. cuniculi</em>, <em>E. intestinalis</em>, <em>Pleistophora </em>spp, <em>Trachipleistophora </em>spp, and <em>Anncaliia [Brachiola] vesicularum</em>)</td> </tr> <tr> <td class="indent1">Drug of choice:<sup>§</sup></td> <td>Albendazole<sup>¶</sup><sup>Δ</sup></td> <td>Immunocompromised: 400 mg orally with fatty meal twice per day for 14 to 28 days. Continue treatment until CD4+ count &gt;200 cells/microL for &gt;6 months after initiation of potent antiretroviral therapy.<br/> Immunocompetent: 400 mg orally with fatty meal twice per day for 7 to 14 days. Symptoms may resolve with no therapy. (Refer to the UpToDate topic on microsporidiosis.)</td> <td>15 mg/kg per day in 2 divided doses (maximum 400 mg/dose)</td> </tr> </tbody></table></div><div class="graphic_lgnd">The mainstay of treatment of microsporidiosis in HIV-infected patients with severe immunosuppression is successful ART for immune restoration of CD4+ counts to greater than 100 cells/microL, which is associated with resolution of symptoms of enteric microsporidiosis, including that caused by <em>E. bieneusi</em>.</div><div class="graphic_footnotes">* Available as an investigational agent (non-US Food and Drug Administration [FDA] approved) in the United States from Leiter's Park Avenue Pharmacy (a custom compounding pharmacy), San Jose, CA (8<font class="baec5a81-e4d6-4674-97f3-e9220f0136c1" style="WHITE-SPACE: nowrap">00-292-6773,</font> <a href="http://www.leiterrx.com" target="_blank">www.leiterrx.com</a>). Ocular lesions due to <em>E. hellem</em> in HIV-infected patients have responded to fumagillin eyedrops prepared from Fumidil B (bicyclohexyl ammonium fumagillin) used to control a microsporidial disease of honey bees.<sup>[1,2]</sup> For lesions due to <em>V. corneae</em>, topical therapy is generally not effective and keratoplasty may be required.<sup>[3]</sup><br/>¶ Not FDA approved for this indication.<br/>Δ For treatment of systemic infection, albendazole must be taken with food; a fatty meal increases oral bioavailability. For treatment of intestinal infection with no systemic involvement, albendazole should be taken on an empty stomach.<br/><font class="lozenge">◊</font> Oral fumagillin (Flisint, Sanofi-Aventis, France) is not available in the United States. It has been effective in treating <em>E. bieneusi</em> in patients with HIV or solid organ transplants<sup>[4,5]</sup> but has been associated with thrombocytopenia and neutropenia. Potent antiretroviral therapy may lead to microbiologic and clinical response in HIV-infected patients with microsporidial diarrhea. Octreotide (Sandostatin) has provided symptomatic relief in some patients with large-volume diarrhea.<br/>§ There is no established treatment for <em>Pleistophora</em>.<sup>[6]</sup> For disseminated disease due to <em>Trachipleistophora</em> or <em>Anncallia</em>, itraconazole 400 mg orally once per day plus albendazole may also be tried.<sup>[7]</sup></div><div class="graphic_reference">References:<br/><ol>
<li>Chan CM, Theng JT, Li L, Tan DT. Microsporidial keratoconjunctivitis in healthy individuals: a case series. Ophtalmology 2003; 110:1420.</li>
<li>Garvey MJ, Ambrose PG, Ulmer JL. Topical fumagillin in the treatment of microsporidial keratoconjunctivitis in AIDS. Ann Pharmacother 1995; 29:872.</li>
<li>Davis RM, Font RL, Keisler MS, Shadduck JA. Corneal microsporidiosis. A case report including ultrastructural observations. Ophthalmology 1990; 97:953.</li>
<li>Molina JM, Tourneur M, Sarfati C, et al. Fumagillin treatment of intestinal microsporidiosis. N Engl J Med 2002; 346:1963.</li>
<li>Lanternier F, Boutboul D, Menotti J, et al. Microsporidiosis in solid organ transplant recipients: two Enterocytozoon bieneusi cases and review. Transpl Infect Dis 2009; 11:83.</li>
<li>Molina JM, Oksenhendler E, Beauvais B, et al. Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS: clinical features and response to albendazole therapy. J Infect Dis 1995; 171:245. </li>
<li>Coyle CM, Weiss LM, Rhodes LV 3rd, et al. Fatal myositis due to the microsporidian Brachiola algerae, a mosquito pathogen. N Engl J Med 2004; 351:42.</li></ol>Adapted with special permission from: Treatment of microsporidiosis. In: Drugs for parasitic infections, 2nd Ed. New Rochelle, NY: The Medical Letter, Inc; 2010:44-45. www.medicalletter.org.<br/>Additional content from: Centers for Disease Control. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR 2009; 58(RR-4):1-207. Available at: <a href="https://www.cdc.gov/mmwr/PDF/rr/rr5804.pdf" target="_blank">http://www.cdc.gov/mmwr/PDF/rr/rr5804.pdf</a>.</div><div id="graphicVersion">Graphic 54051 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
